Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICLONEX: Niclosamide in Hospitalized COVID-19 Patients
NCT04558021Phase 3Unknown
- Sponsor
- Imuneks Farma
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Niclosamide Arm with Placebo Arm (2 arms). Primary endpoint: Physician's judgment on clinical recovery. Status: unknown.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04558021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558021.